...Application for Phase 1/2a Clinical Trial of IMM-1-104 to...
Immuneering aims to create medicines forallpatients with solid tumors driven by RAS mutations and other MAPK pathway activation events. Immuneering has more than a decade of experience applying translational bioinformatics to ge...